<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03785080</url>
  </required_header>
  <id_info>
    <org_study_id>NOAC-GAP</org_study_id>
    <nct_id>NCT03785080</nct_id>
  </id_info>
  <brief_title>Non-warfarin Oral AntiCoagulant Resumption After Gastrointestinal Bleeding in Atrial Fibrillation Patients</brief_title>
  <acronym>NOAC-GAP</acronym>
  <official_title>Non-warfarin Oral AntiCoagulant Resumption After Gastrointestinal Bleeding in Atrial Fibrillation Patients (NOAC-GAP) - a Randomised Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current clinical society guidelines and statements are non-specific and relatively open-ended&#xD;
      regarding the optimal timing to restart non-warfarin oral anticoagulant (NOAC) after&#xD;
      gastrointestinal bleeding (GIB) in patients with atrial fibrillation (AF) who require the&#xD;
      prophylactic medication for stroke prevention. These patients are at increased risk for&#xD;
      devastating future thromboembolic events including stroke if NOAC is not resumed promptly,&#xD;
      whilst premature resumption of anticoagulants can result in recurrent GIB, haemorrhage,&#xD;
      anaemia, myocardial ischaemia and infarction in those with ischaemic heart disease, and even&#xD;
      death. However, the question as to how early a NOAC can be safely restarted after acute GIB&#xD;
      has not been previously answered, and there remains an important knowledge gap.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effectiveness and relative safety of NOACs have been demonstrated in large international&#xD;
      studies where reductions in the incidence of stroke in patients with AF have been reported.&#xD;
      However, the benefits of an anticoagulant are offset by increased incident rates of bleeding&#xD;
      including gastrointestinal bleeding (GIB) and, less commonly, intracranial bleeding,&#xD;
      warranting careful anticoagulation management during periods when patients are susceptible to&#xD;
      the risks for bleeding, stroke and thromboembolism.&#xD;
&#xD;
      The exact duration for withholding NOAC after acute GIB is unknown and in general, current&#xD;
      clinical society guidelines and statements are non-specific and relatively open-ended&#xD;
      regarding the optimal timing to restart non-warfarin oral anticoagulant (NOAC) after&#xD;
      gastrointestinal bleeding (GIB) in patients with atrial fibrillation (AF) who require the&#xD;
      prophylactic medication for stroke prevention. These patients are at increased risk for&#xD;
      devastating future thromboembolic events including stroke if NOAC is not resumed, whilst&#xD;
      premature resumption of anticoagulants can result in recurrent GIB, haemorrhage, anaemia,&#xD;
      myocardial ischaemia and infarction in those with ischaemic heart disease, and even death.&#xD;
&#xD;
      The purpose of this study is to determine if restarting NOAC very early after endoscopic&#xD;
      haemostasis of bleeding peptic ulcer lesions is equivalent to early resumption in AF patients&#xD;
      in terms of safety and efficacy for prevention of recurrent bleeding freedom from GIB&#xD;
      recurrence, while maintaining undiminished benefits in reducing incident rates of systemic&#xD;
      thromboembolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrent gastrointestinal bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>melaena and/or haematemesis with drop in Hb &gt;2g/dL and confirmation of bleeding by endoscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrent gastrointestinal bleeding</measure>
    <time_frame>90 days</time_frame>
    <description>melaena and/or haematemesis with drop in Hb &gt;2g/dL and confirmation of bleeding by endoscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke or transient ischaemic attack</measure>
    <time_frame>30 days</time_frame>
    <description>an acute episode of neurologic deficit of presumed vascular or cardioembolic origin; its presence will be confirmed by a member of the neurology service</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic thromboembolism</measure>
    <time_frame>30 days</time_frame>
    <description>any clinical and/or radiographic acute stroke and/or an acute peripheral arterial thromboembolic event including acute limb ischaemia, coronary embolism and arterial thromboembolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>6 months</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">552</enrollment>
  <condition>Upper Gastrointestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>restart NOAC very early</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>restart NOAC within 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>restart NOAC early</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>restart NOAC at 72 - 84 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>restart NOAC very early</intervention_name>
    <description>withhold NOAC less than 24 hours Post OGD</description>
    <arm_group_label>restart NOAC very early</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>restart NOAC early</intervention_name>
    <description>withhold NOAC for 72 to 84 hours Post OGD</description>
    <arm_group_label>restart NOAC early</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 years&#xD;
&#xD;
          -  History of AF&#xD;
&#xD;
          -  Taking any kind of NOAC at the time of index acute GIB&#xD;
&#xD;
          -  Acute upper GIB (non-variceal bleeding lesions accounting for the GIB) with or without&#xD;
             endoscopic treatment confirmed endoscopic haemostasis verified by GI specialist&#xD;
&#xD;
          -  Patient or next-of-kin able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant stroke (including TIA) at the time of index GIB&#xD;
&#xD;
          -  Requiring bridging IV heparin therapy&#xD;
&#xD;
          -  Portal hypertension&#xD;
&#xD;
          -  Known bleeding diathesis&#xD;
&#xD;
          -  Other conditions precluding use of NOAC at the time of randomisation&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Tumour bleeding&#xD;
&#xD;
               -  Antidote administration to reverse anticoagulation effect of NOACs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph SUNG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CUHK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bing Yee SUEN, BSN</last_name>
    <phone>+852 3505 2640</phone>
    <email>suenbingyee@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming Yeung HO, BSc</last_name>
    <phone>+852 2637 1398</phone>
    <email>andrewho@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Blacktown Hospital</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond KWOK, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endoscopy Center, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph SUNG, MD</last_name>
      <phone>+852 3505 3132</phone>
      <email>jjysung@cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Bing Yee SUEN, BSN</last_name>
      <phone>+852 3505 2640</phone>
      <email>suenbingyee@cuhk.edu.hk</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph SUNG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik FUNG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jimmy SO</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>Singapore</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Joseph JY SUNG</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gastrointestinal bleeding</keyword>
  <keyword>stroke</keyword>
  <keyword>thromboembolism</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>NOAC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

